Kidney medicineOct 17, 2026

Key Treatments for Advanced Type 2 Diabetes and Severe Kidney Disease: Too Late or Still Possible to Start?

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Oct 18, 2026

Abstract

Current evidence supports a monitoring-based approach to 4-pillar therapy in chronic kidney disease (CKD) G4.

The 4-pillar therapy includes renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, the mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide 1 receptor agonists.
Landmark trials primarily involved participants with estimated glomerular filtration rates of approximately 20-30 mL/min/1.73 m², leading to uncertainty in CKD stages G4-G5.
An implementation gap exists in advanced CKD, characterized by missed therapy initiation, interruptions during complications, and failure to reinitiate treatments post-acute triggers.
The review integrates various analyses, including subgroup data from trials and observational studies, to assess the applicability of therapies in CKD G4-G5.
In CKD G5, treatment decisions are more individualized and require careful extrapolation from existing evidence.

Simplified

The 4-pillar therapy-renin-angiotensin system inhibitors, sodium-glucose cotransporter 2 inhibitors, the nonsteroidal mineralocorticoid receptor antagonist finerenone, and glucagon-like peptide 1 receptor agonists-is increasingly applied to improve kidney and cardiovascular outcomes in adults with type 2 diabetes and chronic kidney disease (CKD). However, landmark trials underpinning current recommendations largely enrolled participants down to estimated glomerular filtration rate thresholds of ∼20-30 mL/min/1.73 m², leaving uncertainty in CKD G4-G5. This uncertainty contributes to an implementation gap in advanced CKD, which is as follows: missing pillars are often not initiated, therapies are interrupted during clinical complications, and they are not reinitiated once acute triggers resolve despite high absolute kidney and cardiovascular risk. This narrative review summarizes what current evidence does-and does not-support for initiating, continuing, temporarily withholding, discontinuing, and reinitiating each pillar in type 2 diabetes and CKD G4-G5. We integrate posthoc and subgroup analyses of landmark trials, meta-analyses, and pooled analyses, including low-estimated glomerular filtration rate strata and observational real-world data. The main practical message is that current evidence generally supports a monitoring-based approach to 4-pillar therapy in CKD G4, whereas decisions in CKD G5 remain more individualized and explicitly extrapolative. For clinicians, the key priority is to identify missing pillars, avoid unnecessary permanent discontinuation, and use structured reinitiation when clinically appropriate.

Full Text

Full text is available at the source.

View Full Text ↗

Key Treatments for Advanced Type 2 Diabetes and Severe Kidney Disease: Too Late or Still Possible to Start?

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief